GSK PLC SP. ADR/2 NEW Cash Flow-to-Debt Ratio
GSK PLC SP. ADR/2 NEW cash flow-to-debt ratio. GSK PLC SP. ADR/2 NEW (GS70) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2026, meaning its operating cash flow of €2.69 Billion could theoretically repay 0% of its total liabilities (€44.56 Billion) in one year. Check GS70 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GSK PLC SP. ADR/2 NEW (2021–2025)
Cash flow-to-debt ratio of GSK PLC SP. ADR/2 NEW from 2021 to 2025. Historical debt coverage capacity for GSK PLC SP. ADR/2 NEW across 5 annual periods. Check GSK PLC SP. ADR/2 NEW cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GSK PLC SP. ADR/2 NEW Cash Flow-to-Debt Ratio by Year (2021–2025)
GSK PLC SP. ADR/2 NEW cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for GSK PLC SP. ADR/2 NEW. For the full cash flow conversion analysis, see GS70 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | €7.74 Billion | €45.16 Billion | ▲ +21.3% |
| 2024 | 0.14x | €6.55 Billion | €46.38 Billion | ▼ -3.5% |
| 2023 | 0.15x | €6.77 Billion | €46.21 Billion | ▼ -1.0% |
| 2022 | 0.15x | €7.40 Billion | €50.05 Billion | ▲ +7.4% |
| 2021 | 0.14x | €7.95 Billion | €57.76 Billion | — |